Ph3 study of FOLFIRI in participants with metastatic colorectal cancer

Phase III Clinical Trial

A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Colon Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer, Rectal Cancer
Trial Number: 06750094
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations